Publication | Closed Access
Real world use of dolutegravir two drug regimens
16
Citations
5
References
2023
Year
Majority of experience is in DTG/3TC stable switch. Minority of patients developed side-effects. Low number of virological failures, one developed integrase inhibitor resistance. Viral failure associated with MTR, commensurate with trial data showing no failure with resistance if DTG/3TC STR used. Overall DTG-2DR demonstrates high efficacy in real-world setting.
| Year | Citations | |
|---|---|---|
Page 1
Page 1